Difference between revisions of "Example orders for CHOEP in lymphoma"
Warner-admin (talk | contribs) m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.'''" to "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.'''") |
Warner-admin (talk | contribs) m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth" to "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span style="font-family:Arial; font-size:200%"> Hello!<br> We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br> Please help us by filling it out!<br> '''Link:''' http://j.mp/2BlBaoQ </span> |}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth") |
||
Line 1: | Line 1: | ||
− | '''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].''' | + | {|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" |
+ | | | ||
+ | <span style="font-family:Arial; font-size:200%"> Hello!<br> | ||
+ | We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br> | ||
+ | Please help us by filling it out!<br> | ||
+ | '''Link:''' http://j.mp/2BlBaoQ | ||
+ | </span> | ||
+ | |}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].''' | ||
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. |
Revision as of 20:41, 30 December 2017
Hello! |
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
CHOEP, CHOPE
CHOEP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Etoposide, Prednisone
Published regimens and references may be found on the Aggressive Non-Hodgkin lymphoma page.
Example regimen #1
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV on day 1
- Vincristine (Oncovin) 2 mg IV on day 1
- Etoposide (Vepesid) 100 mg/m2 IV on days days 1-3
- Prednisone (Sterapred) 100 mg PO on days 1 to 5
- Patients with initial bulky disease (mass conglomerate at least 7.5 cm) received 36 Gy radiation therapy and to extranodal sites of disease when possible
21-day cycles x 6 cycles
Supportive medications
- Fosaprepitant (Emend injection) 150 mg IV x1 on day 1 prior to chemotherapy
- Ondansetron (Zofran) 8 mg IV 30 minutes prior to chemotherapy
- Allopurinol (Aloprim) as described below
Hydration:
- 500 ml NS and/or D5W KVO rate to be used as running IV for chemotherapy infusion. Give up to 500 ml NS and/or D5W.
Monitoring:
- On days 1, 3, 8, and 17 of cycle 1: CBC with differential, absolute neutrophil count (ANC), comprehensive metabolic panel (chem 10 and LFTs), LDH, uric acid; future labs to be determined based on patient's cycle 1 counts
- Prior to start of therapy, check beta-2 microglobulin, SPEP, IgG, IgA, IgM
- Initial staging with CT torso & bone marrow biopsy
- In anticipation of rituxan use starting cycle 2, check hepatitis B surface antibody (HbsAb), hepatitis B surface antigen (HbsAg), hepatitis B core antibody (HbcAb), hepatitis C antibody (HCV Ab)
Outpatient medications:
- Acyclovir (Zovirax) 400 mg PO TID
- Allopurinol (Aloprim) 300 mg PO daily
- Filgrastim (Neupogen) 300 mcg (patient is 63 kg) SC daily on days 4-13
- Ondansetron (Zofran) 8 mg PO TID
- Pantoprazole (Protonix) 40 mg PO daily
- Prednisone (Sterapred) as described above
- Docusate (Colace) 100 mg PO BID prn constipation
- Sennosides (Senna) 8.6 mg PO Q8H prn constipation
Clinical scenario & comments:
- 44 year-old lady with primary mediastinal lymphoma; 7 cm anterior mediastinal mass, ECOG performance status 0.